% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • ametrosixual ametrosixual Jul 1, 2013 2:53 PM Flag

    ``Nevermind Arikase Superiority SORRY MY BAD``- CEO


    Insmed’s Arikace met the primary endpoint of non-inferiority to Novartis AG (NOVN)’s Tobi in a late-stage study of cystic fibrosis patients with the bacterial infection Pseudomonas aeruginosa, the Monmouth Junction, New Jersey-based company said today in a statement. Earlier study results suggested the drug might establish superiority as a treatment compared with Novartis’s therapy, said Gregory R. Wade, an analyst at Wedbush Securities Inc.

    “That would have done two things: it would have improved its competitiveness in the marketplace, and it would have sped the rate at which it can make a registration filing in the United States,” Wade said.

    This topic is deleted.
16.59+0.55(+3.43%)Nov 25 4:00 PMEST